Genmab A/S (GMAB) - Total Assets

Latest as of September 2025: Dkr7.02 Billion DKK ≈ $1.10 Billion USD

Based on the latest financial reports, Genmab A/S (GMAB) holds total assets worth Dkr7.02 Billion DKK (≈ $1.10 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Genmab A/S - Total Assets Trend (2002–2024)

This chart illustrates how Genmab A/S's total assets have evolved over time, based on quarterly financial data. Also see market cap of Genmab A/S for the company's overall valuation and market capitalisation.

Genmab A/S - Asset Composition Analysis

Current Asset Composition (December 2024)

Genmab A/S's total assets of Dkr7.02 Billion consist of 60.8% current assets and 39.2% non-current assets. Review Genmab A/S (GMAB) financial obligations to assess the company's total debt and financial obligations.

Asset Category	Amount (DKK)	% of Total Assets
Cash & Equivalents	Dkr0.00	21.5%
Accounts Receivable	Dkr6.59 Billion	14.4%
Inventory	Dkr62.00 Million	0.1%
Property, Plant & Equipment	Dkr0.00	0.0%
Intangible Assets	Dkr12.34 Billion	26.9%
Goodwill	Dkr2.54 Billion	5.5%

Asset Composition Trend (2002–2024)

This chart illustrates how Genmab A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Genmab A/S share price for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Genmab A/S's current assets represent 60.8% of total assets in 2024, a decrease from 89.6% in 2002.
Cash Position: Cash and equivalents constituted 21.5% of total assets in 2024, up from 16.0% in 2002.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 4.0% in 2002.
Asset Diversification: The largest asset category is intangible assets at 26.9% of total assets.

Genmab A/S Competitors by Total Assets

Key competitors of Genmab A/S based on total assets are shown below.

Company	Country	Total Assets
argenx NV ADR NASDAQ:ARGX	USA	$10.03 Billion
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	USA	$1.26 Billion
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	China	CN¥37.98 Billion
Halozyme Therapeutics Inc NASDAQ:HALO	USA	$2.22 Billion
Tubize-Fin BR:TUB	Belgium	€1.99 Billion
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	USA	$792.26 Million
Nanobiotix NASDAQ:NBTX	USA	$67.76 Million
Innovita Biological Technology Co. Ltd. A SHG:688253	China	CN¥2.23 Billion

Genmab A/S - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	6.03	5.17	15.00
Quick Ratio	6.01	5.15	15.20
Cash Ratio	0.00	0.00	0.00
Working Capital	Dkr3.73 Billion	Dkr19.11 Billion	Dkr17.54 Billion

Genmab A/S - Advanced Valuation Insights

This section examines the relationship between Genmab A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	3.24
Latest Market Cap to Assets Ratio	0.45
Asset Growth Rate (YoY)	29.8%
Total Assets	Dkr45.81 Billion
Market Capitalization	$20.72 Billion USD

Valuation Analysis

Below Book Valuation: The market values Genmab A/S's assets below their book value (0.45x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Genmab A/S's assets grew by 29.8% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Genmab A/S (2002–2024)

The table below shows the annual total assets of Genmab A/S from 2002 to 2024.

Year	Total Assets	Change
2024-12-31	Dkr45.81 Billion ≈ $7.17 Billion	+29.82%
2023-12-31	Dkr35.29 Billion ≈ $5.52 Billion	+17.17%
2022-12-31	Dkr30.12 Billion ≈ $4.71 Billion	+22.30%
2021-12-31	Dkr24.63 Billion ≈ $3.85 Billion	+16.48%
2020-12-31	Dkr21.14 Billion ≈ $3.31 Billion	+39.61%
2019-12-31	Dkr15.14 Billion ≈ $2.37 Billion	+78.99%
2018-12-31	Dkr8.46 Billion ≈ $1.32 Billion	+28.14%
2017-12-31	Dkr6.60 Billion ≈ $1.03 Billion	+26.05%
2016-12-31	Dkr5.24 Billion ≈ $819.56 Million	+34.23%
2015-12-31	Dkr3.90 Billion ≈ $610.58 Million	+36.13%
2014-12-31	Dkr2.87 Billion ≈ $448.51 Million	+65.56%
2013-12-31	Dkr1.73 Billion ≈ $270.91 Million	+2.28%
2012-12-31	Dkr1.69 Billion ≈ $264.86 Million	+8.21%
2011-12-31	Dkr1.56 Billion ≈ $244.77 Million	-36.96%
2010-12-31	Dkr2.48 Billion ≈ $388.26 Million	+11.71%
2009-12-31	Dkr2.22 Billion ≈ $347.58 Million	-31.83%
2008-12-31	Dkr3.26 Billion ≈ $509.89 Million	-17.68%
2007-12-31	Dkr3.96 Billion ≈ $619.38 Million	+119.37%
2006-12-31	Dkr1.80 Billion ≈ $282.35 Million	+31.68%
2005-12-31	Dkr1.37 Billion ≈ $214.41 Million	+7.75%
2004-12-31	Dkr1.27 Billion ≈ $199.00 Million	+7.78%
2003-12-31	Dkr1.18 Billion ≈ $184.64 Million	-25.46%
2002-12-31	Dkr1.58 Billion ≈ $247.69 Million	--

About Genmab A/S

CO:GMAB Denmark Biotechnology

Market Cap

$20.72 Billion

Dkr132.44 Billion DKK

Market Cap Rank

#1245 Global

#8 in Denmark

Share Price

Dkr2150.00

Change (1 day)

+1.61%

52-Week Range

Dkr1524.00 - Dkr2251.00

All Time High

Dkr3295.00